Reference 1: Total Neoadjuvant Therapy for Locally
Advanced Rectal Cancer: Induction or
Consolidation Chemotherapy?
Amr Aref, MD1,2 and Ahmed Abdalla, MD3http://ascopubs.org/doi/full/10.1200/JCO.22.00506 Reference 2: Organ Preservation in Patients With
Rectal Adenocarcinoma Treated With Total
Neoadjuvant Therapy
Julio Garcia-Aguilar, MD, PhD1; Sujata Patil, PhD2; Marc J. Gollub, MD3; Jin K. Kim, MD1; Jonathan B. Yuval, MD1;
Hannah M. Thompson, MD1; Floris S. Verheij, MD1; Dana M. Omer, MD1; Meghan Lee, BS1; Richard F. Dunne, MD4; Jorge Marcet, MD5;
Peter Cataldo, MD6; Blase Polite, MD7; Daniel O. Herzig, MD8; David Liska, MD9; Samuel Oommen, MD10; Charles M. Friel, MD11;
Charles Ternent, MD12; Andrew L. Coveler, MD13; Steven Hunt, MD14; Anita Gregory, MD15; Madhulika G. Varma, MD16;
Brian L. Bello, MD17; Joseph C. Carmichael, MD18; John Krauss, MD19; Ana Gleisner, MD20; Philip B. Paty, MD1; Martin R. Weiser, MD1;
Garrett M. Nash, MD1; Emmanouil Pappou, MD1; Jos ´e G. Guillem, MD21; Larissa Temple, MD22; Iris H. Wei, MD1; Maria Widmar, MD1;
Sabrina Lin, MS2; Neil H. Segal, MD, PhD23; Andrea Cercek, MD23; Rona Yaeger, MD23; J. Joshua Smith, MD, PhD1;
Karyn A. Goodman, MD24; Abraham J. Wu, MD25; and Leonard B. Saltz, MD23Accepted on March
17, 2022 and
published at
ascopubs.org/journal/
jco on April 28, 2022:
DOI https://doi.org/10.
1200/JCO.22.00032 Reference 3: NCCN guidelines